Isracann Biosciences Inc.  (CSE:IPOT) (XFRA:A2PT0E) (OTC:ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales, is pleased to announce its entry into a joint venture agreement (the “JV Agreement”) resulting in a phased partnership of two near-term farm operations located in the Sharon Plain region of Israel. Today’s announcement positions the Company for revenue generating opportunities earlier than previously planned with the Company’s current development project in Nir Israel.

The Israel Medical Cannabis (IMC) compliant farm properties operates under preliminary cannabis nursery and cultivation licenses and are preparing to commence planting within weeks. The farms are contiguously located and together currently maintain a total of over 160,000 sq. ft. of greenhouse canopy along with related infrastructure facilities. These greenhouses are located on a 2,000,000 sq. ft. parcel of private land, with the potential for expanded production and processing operations. Private lands are rarely available in Israel and are free from the requirement of land commission regulatory approval, thereby minimizing licensing delays.


The joint venture partner/operator is a regionally well-known, highly respected and active cannabis grower. The principals of the local partner enjoy a family history of building and operating greenhouse operations across the middle east and proven sector ability with over 2-years experience as owners of a stable and productive cannabis farm servicing the domestic Israeli market. Their technical proficiency includes an active tissue culture program and most importantly, has resulted in securing critical plant genetics which will be available to the JV operation.

All aspects of the operations are regulatory compliant with the greenhouse facilities constructed to IMC-GAP and IMC-GMP standards including security procedures which are in accordance with IMC-GSP regulations. The entire operation is designed for EU-GMP certification and Isracann’s EU-GMP consultants will be reviewing all necessary protocols for future export operations. Based on existing parameters, full scale production targets a combined total projected yield of 12,600kg of dried cannabis flow per year. Based on scheduled planting commencing in Q2 this year, initial sales could initiate by early Q3, 2020, reducing the anticipated time-to-market in Isracann’s strategic plans.

The terms of the joint venture include a non-dilutive agreement with a purchase price of 4 million ILS (Israeli Shekel) or approximately CAD$1.5 million to acquire 50% of the Sharon Plain operation subject to pending Israeli Medical Cannabis Agency (IMCA) approval. Subsequently, upon commercial commencement of production an additional 3 million ILS or approximately CAD$1.2M payment will be due. The joint venture will equally share both operating costs and revenue through participation in a number of agreements comprising construction services, growing services, land lease agreements, IMCA licenses, and a number of sub agreements establishing and defining the various rights of all parties.

Company CEO, Darryl Jones states, “During our recent visit to Israel we were able to enter into prolonged and detailed face-to-face discussion with our new partners. After an extensive review of the operations and the overall agronomic, legal and financial situation, we felt the opportunity to work with our new partners combined with ramping up sales so much faster than anticipated was absolutely worth it both in the short term as well as part of a smart long term strategy. From a sales perspective, there have been industry reports discussing plans to import medical cannabis from Canada into Israel which clearly demonstrates growing domestic demand. Plus, the ability to export into European markets continues to be a major part of our business development objectives. As of this announcement today, with facilities, permits, approvals and partners in-place, we have officially launched our commercial activities in Israel and beyond.”

The JV complements the Company’s existing medical cannabis project in Nir Israel pursuant to its joint venture agreements held by its wholly owned Israeli subsidiary, Cannisra Holdings Ltd. The Cannisra project will be a bespoke cultivation project to which the Company has spent significant time, effort and expense planning, designing and making regulatory application for the development of the cultivation facility.

ON BEHALF OF THE BOARD OF DIRECTORS

“Darryl Jones”

Darryl Jones
Chief Executive Officer and President

About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel’s agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.

Contact
Investor Relations
Toll Free: +1 855.205.0226
Email: inquiries@isracann.com
Web:  www.isracann.com

Click here to connect with Isracann Biosciences Inc. (CSE:IPOT) for an Investor Presentation.

Source

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005322/en/

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (“ HempFusion ” or the “ Company ”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its wholly owned subsidiary, Probulin Probiotics, LLC (“ Probulin ”), has increased its product selection in certain brick and mortar locations and expanded its distribution on Amazon through a unique eCommerce store within the Amazon platform. The broader product selection is available in major brick and mortar stores including Sprouts and Fresh Thyme and includes the Company’s new Probulin Total Care Immune product.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005411/en/

Keep reading... Show less

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to report third party confirmatory studies that the active ingredient in MustGrow’s mustard plant-based technology, Allyl Isothiocyanate (“AITC”), has a positive impact on soil health, contributing to the environmental and ecological security of both our plant-based food supply and the planet. Application of natural AITC returns organic plant material to the soil through its pre-plant treatment process as a potential alternative to using synthetic chemicals.

Soil micro-organisms play an important role in soil fertility and plant health, contributing to natural soil processes including the formation of organic matter and nutrient transformation. Human activities, including chemical pesticide use, can adversely impact the soil microbial diversity and structure.

Keep reading... Show less

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that its subsidiary CannaCure Corp. (“CannaCure”) has entered into a binding letter of intent with Entourage Participações S.A. (“Entourage Phytolab”) for a three-year extraction and finished product supply agreement (the “Agreement”) for the distribution of pharmaceutical products in Brazil.

Under the terms of the Agreement, Heritage will supply to Entourage Phytolab, hemp-derived CBD dominant extract, cannabis-derived THC dominant extract, and hemp-derived CBD 25 mg softgels and cannabis-derived THC dominant 2.5 and 5.0 mg softgels.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) Is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF”. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE. Shares of Better Plant are available on the FSE under the symbol “YG3”.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/72301_betterplanta.jpg

Keep reading... Show less